398 related articles for article (PubMed ID: 10571777)
1. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy.
Al-Douahji M; Brugarolas J; Brown PA; Stehman-Breen CO; Alpers CE; Shankland SJ
Kidney Int; 1999 Nov; 56(5):1691-9. PubMed ID: 10571777
[TBL] [Abstract][Full Text] [Related]
2. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
3. The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy.
Kuan CJ; al-Douahji M; Shankland SJ
J Am Soc Nephrol; 1998 Jun; 9(6):986-93. PubMed ID: 9621281
[TBL] [Abstract][Full Text] [Related]
4. The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis.
Kim YG; Alpers CE; Brugarolas J; Johnson RJ; Couser WG; Shankland SJ
Kidney Int; 1999 Jun; 55(6):2349-61. PubMed ID: 10354282
[TBL] [Abstract][Full Text] [Related]
5. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
Mizuno S; Nakamura T
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
[TBL] [Abstract][Full Text] [Related]
6. Tubular cell senescence and expression of TGF-beta1 and p21(WAF1/CIP1) in tubulointerstitial fibrosis of aging rats.
Ding G; Franki N; Kapasi AA; Reddy K; Gibbons N; Singhal PC
Exp Mol Pathol; 2001 Feb; 70(1):43-53. PubMed ID: 11170790
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor alpha-mediated events promote sex-specific diabetic glomerular hypertrophy.
Lovegrove AS; Sun J; Gould KA; Lubahn DB; Korach KS; Lane PH
Am J Physiol Renal Physiol; 2004 Sep; 287(3):F586-91. PubMed ID: 15149972
[TBL] [Abstract][Full Text] [Related]
8. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
9. Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition.
Sassy-Prigent C; Heudes D; Jouquey S; Auberval D; Belair MF; Michel O; Hamon G; Bariety J; Bruneval P
Lab Invest; 1995 Jul; 73(1):64-71. PubMed ID: 7603042
[TBL] [Abstract][Full Text] [Related]
10. Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease.
Menini S; Iacobini C; Oddi G; Ricci C; Simonelli P; Fallucca S; Grattarola M; Pugliese F; Pesce C; Pugliese G
Diabetologia; 2007 Dec; 50(12):2591-9. PubMed ID: 17901943
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis.
Monkawa T; Pippin J; Yo Y; Kopp JB; Alpers CE; Shankland SJ
Nephron Exp Nephrol; 2006; 102(1):e8-18. PubMed ID: 16179805
[TBL] [Abstract][Full Text] [Related]
12. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.
Baba M; Wada J; Eguchi J; Hashimoto I; Okada T; Yasuhara A; Shikata K; Kanwar YS; Makino H
J Am Soc Nephrol; 2005 Nov; 16(11):3222-34. PubMed ID: 16177004
[TBL] [Abstract][Full Text] [Related]
13. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
Meier M; Park JK; Overheu D; Kirsch T; Lindschau C; Gueler F; Leitges M; Menne J; Haller H
Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
[TBL] [Abstract][Full Text] [Related]
14. [Influence of irbesartan on renal hypertrophy and thickening of glomerular basement-membrane in streptozotocin-induced diabetic rats].
Liu BC; Luo DD; Sun J; Ma KL; Ruan XZ
Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):320-3. PubMed ID: 12882713
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.
Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H
Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390
[TBL] [Abstract][Full Text] [Related]
16. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy.
Wang SN; LaPage J; Hirschberg R
Kidney Int; 2000 Mar; 57(3):1002-14. PubMed ID: 10720953
[TBL] [Abstract][Full Text] [Related]
17. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes.
Park IS; Kiyomoto H; Abboud SL; Abboud HE
Diabetes; 1997 Mar; 46(3):473-80. PubMed ID: 9032105
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.
Sharma K; Jin Y; Guo J; Ziyadeh FN
Diabetes; 1996 Apr; 45(4):522-30. PubMed ID: 8603776
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of diabetic renal hypertrophy.
Wolf G; Ziyadeh FN
Kidney Int; 1999 Aug; 56(2):393-405. PubMed ID: 10432377
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy.
Shah A; Xia L; Masson EA; Gui C; Momen A; Shikatani EA; Husain M; Quaggin S; John R; Fantus IG
J Am Soc Nephrol; 2015 Dec; 26(12):2963-77. PubMed ID: 25855771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
